Business Context and Reporting Period
This Form 8-K Current Report was filed by Disc Medicine, Inc. (Nasdaq: IRON) on February 7, 2024. The report discloses significant changes in executive leadership, specifically the appointment of a new Chief Financial Officer and the promotion of an internal executive to Chief Operating Officer.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on personnel changes and associated compensation arrangements.
Material Changes
Executive Leadership Changes
- Chief Financial Officer (CFO): Jean M. Franchi was appointed as CFO, Treasurer, principal financial officer, and principal accounting officer, effective February 7, 2024. She succeeds Joanne Bryce, who departed on the same date.
- Chief Operating Officer (COO): Jonathan Yu, previously the Chief Business Officer, was promoted to COO and principal operating officer, effective February 7, 2024.
Compensation and Inducement Awards
Ms. Franchi's employment agreement includes the following material terms:
- Base Salary: $515,000 annually.
- Signing Bonus: One-time payment of $75,000.
- Annual Bonus: Target amount of 40% of base salary.
- Stock Options: Grant of 55,000 options to purchase common stock. Vesting schedule: 25% on the first anniversary, with the remainder vesting in equal monthly installments over 36 months.
- Restricted Stock Units (RSUs): Grant of 36,666 RSUs. Vesting schedule: 25% on each of the first four anniversaries of the vesting date.
- Regulatory Note: The stock awards are classified as inducement awards under NASDAQ Listing Rule 5635(c)(4) and are granted outside the Company's 2021 Stock Option and Incentive Plan.
Guidance, Outlook, and Risks
The filing contains no financial guidance, forward-looking outlook, or discussion of material risks and contingencies. The document is limited to the disclosure of the executive appointments and the terms of the new CFO's employment agreement.
Investor Verification Checklist
- Verify the departure date and transition plan for the outgoing CFO, Joanne Bryce.
- Review the full text of the Employment Agreement (Exhibit 10.1) for additional terms not summarized in the 8-K.
- Confirm the vesting conditions and performance metrics (if any) attached to the 55,000 stock options and 36,666 RSUs granted to Ms. Franchi.
- Assess the impact of the new executive leadership on the company's strategic direction and financial management.